Sofinnova Partners Raises €1.2 Billion to Drive Life Sciences Innovation
Sofinnova Partners, a leading European venture capital firm specializing in life sciences, has announced the successful raising of €1.2 billion over the past year across its diverse investment strategies. This includes more than €1 billion secured in the last quarter alone. As a result, the firm’s assets under management (AUM) have surpassed €4 billion, cementing Sofinnova’s position as a key player in supporting transformative innovation within healthcare and sustainability. Further details on the individual funds will be revealed once their final closings occur.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, expressed his excitement, saying, “All seven of Sofinnova’s investment strategies—from incubation to later-stage growth, covering biotech, medtech, industrial biotech, and digital medicine—now have the capital to back the next generation of life sciences companies.” He added, “With these new funds, we aim to support 50 to 60 new companies, empowering a new wave of entrepreneurs who are addressing some of the world’s most pressing health and sustainability challenges.”
The new funds have garnered substantial backing from a diverse group of investors, including leading institutional investors, sovereign wealth funds, corporates, and family offices. This strong commitment highlights the confidence investors have in Sofinnova’s ability to identify and foster high-potential opportunities in the life sciences sector.
Sofinnova Partners has spent the past decade building one of the most experienced and globally connected teams in life sciences investing. The firm is now composed of over 80 professionals, including 25 investment partners with deep expertise in the sector. This diverse, international team spans 24 nationalities and operates out of three key European offices, with additional presence in important innovation hubs around the world. This broad network gives Sofinnova a unique ability to identify and support innovative companies globally.
As part of its strategic evolution, Sofinnova is also leveraging advanced technology to enhance its investment process. The firm has recently launched Sofinnova.ai, an AI-powered platform that has been in development for the past five years.
This cutting-edge platform is revolutionizing how Sofinnova sources, analyzes, and supports breakthrough science and entrepreneurs. By utilizing advanced data analytics and machine learning, Sofinnova is strengthening its ability to identify disruptive innovations and accelerate the growth of pioneering life sciences companies.
The firm’s ability to combine deep sector expertise with innovative technologies positions it to continue playing a vital role in the future of life sciences. Its funds span various stages of investment, from early-stage incubation to later-stage growth. This allows Sofinnova to provide the necessary financial and strategic support to companies at any phase of their development. The firm is particularly focused on identifying businesses with the potential to make a meaningful impact on global health and sustainability challenges, including advances in biotech, medtech, industrial biotechnology, and digital medicine.
Sofinnova’s longstanding track record speaks to its effectiveness as a venture capital firm. Since its founding in 1972, the firm has backed over 500 companies, helping to create global market leaders in various sectors. With over 50 years of experience, Sofinnova has developed a reputation for its hands-on approach and ability to work closely with entrepreneurs to build transformative businesses.
The firm’s deep expertise in both healthcare and sustainability reflects its commitment to addressing some of the most urgent issues facing society. As the life sciences landscape evolves, Sofinnova Partners continues to be a vital contributor to innovation, combining its investment capital with its scientific, medical, and business expertise to support companies that will shape the future of healthcare and environmental sustainability.
Today, Sofinnova Partners manages over €4 billion in assets, with a broad portfolio that spans multiple high-growth sectors. This latest round of funding further strengthens the firm’s position as a leading investor in life sciences, positioning it well to continue supporting the next generation of entrepreneurs who are developing life-changing technologies. As Sofinnova moves forward, it remains committed to identifying, nurturing, and accelerating breakthrough innovations that will have a lasting positive impact on global health and sustainability.
About Sofinnova Partners
Sofinnova Partners is a premier European venture capital firm focused on life sciences, specializing in healthcare and sustainability investments. Headquartered in Paris, with offices in London and Milan, the firm’s team of professionals brings extensive scientific, medical, and business expertise to the table. Sofinnova Partners is known for its hands-on approach, partnering with ambitious entrepreneurs as a lead or cornerstone investor across the full spectrum of life sciences, from seed to later-stage companies. The firm has been active for over 50 years, backing more than 500 companies and helping create market leaders globally. Today, Sofinnova Partners manages over €4 billion in assets.
